Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07520006) titled 'Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies' on April 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Nurix Therapeutics, Inc.
Condition:
B-cell Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Intervention:
Drug: NX-5948
Drug: venetoclax
Drug: rituximab
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: May 2026
Target Sample Size: 150
To know more, visit https://clinicaltri...